



Gubra publishes financial calendar for 2023

With reference to company announcement dated 20 March 2023 related to the publication of a prospectus for its initial public offering and listing of the shares of Gubra A/S (the "**Company**" or "**Gubra**") on Nasdaq Copenhagen and announcement dated 30 March 2023 related to the result of the offering, Gubra hereby publishes its financial calendar for 2023:

Trading statement first quarter 2023:	11 May 2023
Half-year report 2023:	25 August 2023
Trading statement third quarter 2023:	8 November 2023
Annual accounts 2023:	28 February 2024
Annual general meeting (AGM) 2024:	3 April 2024

Contacts

Media: Sofia Pitt Boserup, sbo@gubra.dk, +45 4188 9586
Investors: Kristian Borbos, kbo@gubra.dk, +45 3080 8035

About Us

Gubra, founded in 2008 in Denmark, is specialized in pre-clinical contract research services and peptide-based drug discovery within metabolic and fibrotic diseases. Gubra's activities are focused on the early stages of drug development and are organised in two business areas - CRO Services and Discovery & Partnerships (D&P). The two business areas are highly synergistic and create a unique entity capable of generating a steady cash flow from the CRO business while at the same time enjoying biotechnology upside in the form of potential development milestone payments and potential royalties from the D&P business. Gubra has approx. 200 employees and had annual revenue of approx. DKK 200 million in 2022. See www.gubra.dk for more information.

Attachments

[Gubra publishes financial calendar for 2023](#)